<DOC>
	<DOCNO>NCT01353027</DOCNO>
	<brief_summary>The purpose study characterize safety pharmacology single administration AVI-6002 , post-exposure prophylaxis candidate treatment Ebolavirus .</brief_summary>
	<brief_title>Safety Study Single Administration Post-Exposure Prophylaxis Treatment Ebola Virus</brief_title>
	<detailed_description>Ebola hemorrhagic fever ( EHF ) rare human disease cause Ebola Virus ( EBOV ) , filamentous single-stranded , negative-sense RNA virus . Since 1976 several Ebolavirus outbreak occur fatality rate range 57 % 90 % , outbreaks trace single EBOV specie ; EBOV-Z . No effective therapy currently available Ebolavirus . AVI-6002 experimental combination 2 phosphorodiamidate morpholino antisense oligomers positive charge select subunit ( PMOplusâ„¢ ) . These oligomers specifically target viral messenger RNA encode 2 Ebolavirus protein think important viral replication host immune suppression . The present study design characterize safety , tolerability pharmacokinetics escalate single-administration dos AVI-6002 healthy human subject .</detailed_description>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>Male female age 18 50 year good general health Volunteers must willing use barrier method contraception nonchildbearing potential Volunteers must willing undergo urine screen drug abuse Pregnancy breastfeed . Any clinically relevant abnormality physical examination , vital sign , ECG , clinical chemistry , hematology urinalysis Positive test human immunodeficiency virus , hepatitis B hepatitis C know history HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>